- Home
- VERA
as of 03-18-2026 3:41pm EST
$38.26
$1.06
-2.71%
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 2.8B | IPO Year: | 2021 |
| Target Price: | $81.30 | AVG Volume (30 days): | 940.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.66 | EPS Growth: | -69.45 |
| 52 Week Low/High: | $18.53 - $56.05 | Next Earning Date: | 05-05-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 445.28% |
| P/E Ratio: | -8.21 | Index: | N/A |
| Free Cash Flow: | -241734000.0 | FCF Growth: | N/A |
AI-Powered VERA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 73.17%
73.17%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Vera Therapeutics Inc. (VERA)
Grant Sean
Sell
CHIEF FINANCIAL OFFICER
VERA Feb 23, 2026
Avg Cost/Share
$41.98
Shares
4,949
Total Value
$207,778.32
Owned After
114,181
SEC Form 4
Fordyce Marshall
Sell
PRESIDENT AND CEO
VERA Feb 23, 2026
Avg Cost/Share
$41.98
Shares
16,925
Total Value
$710,577.51
Owned After
257,163
SEC Form 4
Brenner Robert
Sell
Chief Medical Officer
VERA Feb 23, 2026
Avg Cost/Share
$41.98
Shares
2,151
Total Value
$90,307.37
Owned After
50,947
SEC Form 4
Young Joseph R
Sell
SVP, FINANCE, CHIEF ACCT OFFCR
VERA Feb 23, 2026
Avg Cost/Share
$41.98
Shares
3,117
Total Value
$130,863.82
Owned After
64,722
SEC Form 4
Turner William D.
Sell
Chief Regulatory Officer
VERA Feb 23, 2026
Avg Cost/Share
$41.98
Shares
2,187
Total Value
$91,818.79
Owned After
45,313
SEC Form 4
JOHNSON DAVID LEE
Sell
Chief Operating Officer
VERA Feb 23, 2026
Avg Cost/Share
$41.98
Shares
2,579
Total Value
$108,276.48
Owned After
45,727
SEC Form 4
Skelton Laurence Matthew
Sell
Chief Commercial Officer
VERA Feb 23, 2026
Avg Cost/Share
$41.98
Shares
1,582
Total Value
$66,418.53
Owned After
64,218
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Grant Sean | VERA | CHIEF FINANCIAL OFFICER | Feb 23, 2026 | Sell | $41.98 | 4,949 | $207,778.32 | 114,181 | |
| Fordyce Marshall | VERA | PRESIDENT AND CEO | Feb 23, 2026 | Sell | $41.98 | 16,925 | $710,577.51 | 257,163 | |
| Brenner Robert | VERA | Chief Medical Officer | Feb 23, 2026 | Sell | $41.98 | 2,151 | $90,307.37 | 50,947 | |
| Young Joseph R | VERA | SVP, FINANCE, CHIEF ACCT OFFCR | Feb 23, 2026 | Sell | $41.98 | 3,117 | $130,863.82 | 64,722 | |
| Turner William D. | VERA | Chief Regulatory Officer | Feb 23, 2026 | Sell | $41.98 | 2,187 | $91,818.79 | 45,313 | |
| JOHNSON DAVID LEE | VERA | Chief Operating Officer | Feb 23, 2026 | Sell | $41.98 | 2,579 | $108,276.48 | 45,727 | |
| Skelton Laurence Matthew | VERA | Chief Commercial Officer | Feb 23, 2026 | Sell | $41.98 | 1,582 | $66,418.53 | 64,218 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 26, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 26, 2026 · 100% conf.
AI Prediction BUY
1D
+1.74%
$43.09
Act: -3.54%
5D
+8.37%
$45.89
Act: -8.26%
20D
+17.09%
$49.59
Price: $42.35 Prob +5D: 100% AUC: 1.000
0001193125-26-073421
8-K
0001831828false00018318282026-02-262026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2026
Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-40407
81-2744449
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2000 Sierra Point Parkway, Suite 1200
Brisbane, California
94005
(Address of principal executive offices)
(Zip Code)
(650) 770-0077 Registrant’s telephone number, including area code
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A common stock, $0.001 par value per share
VERA
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On February 26, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the full year ended December 31, 2025, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release of Vera Therapeutics, Inc., dated February 26, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Vera Therapeutics, Inc.
Date:
February 26, 2026
By:
/s/ Sean Grant
Sean Grant, Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 5, 2025
0001193125-25-265799
8-K
0001831828false00018318282025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2025
Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-40407
81-2744449
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2000 Sierra Point Parkway, Suite 1200
Brisbane, California
94005
(Address of principal executive offices)
(Zip Code)
(650) 770-0077 Registrant’s telephone number, including area code
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A common stock, $0.001 par value per share
VERA
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 5, 2025, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release of Vera Therapeutics, Inc., dated November 5, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Vera Therapeutics, Inc.
Date:
November 5, 2025
By:
/s/ Sean Grant
Sean Grant, Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 5, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 5, 2025
0000950170-25-102399
8-K
0001831828false00018318282025-08-052025-08-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 5, 2025
Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-40407
81-2744449
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2000 Sierra Point Parkway, Suite 1200
Brisbane, California
94005
(Address of principal executive offices)
(Zip Code)
(650) 770-0077 Registrant’s telephone number, including area code
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A common stock, $0.001 par value per share
VERA
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 5, 2025, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release of Vera Therapeutics, Inc., dated August 5, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Vera Therapeutics, Inc.
Date:
August 5, 2025
By:
/s/ Sean Grant
Sean Grant, Chief Financial Officer
Latest Vera Therapeutics Inc. News
VERA Breaking Stock News: Dive into VERA Ticker-Specific Updates for Smart Investing
Compare VERA vs Leading Stocks
See how VERA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VERA Vera Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.